查看文章

Doripenem DD NA NA NA NA 35.5 30.8 0.9 NA 7.5 0.0 0.0 11.2 ET 32 32 NA NA NA NA 6.5 2.8 0.0 NA 6.5 0.0 0.0 8.4 Vitek 2 8 8 NA NA NA NA 21.5 17.8 0.0 NA 21.5 1.9 0.0 20.6 BMD 16 16 NA 3.7 3.7 a DD, disk diffusion; ET, Etest; Vitek 2, Vitek 2 cards (AST-GN24 card and AST-XN04 extension card). b S, susceptible; VME, very major errors; ME, major errors; mE, minor errors; NA, not applicable (intermediate breakpoints for doripenem were not defined). c CLSI breakpoints for imipenem/meropenem were as follows: for susceptibility, 4 g/ml (16 mm); for intermediacy, 8 g/ml (14 to 15 mm); for resistance, 16 g/ml (13 mm)(3). d FDA breakpoints were as follows: for imipenem/meropenem, 4 g/ml (16 mm) for susceptibility, 8 g/ml (14 to 15 mm) for intermediacy, and 16 g/ml (13 mm) for resistance; for susceptibility to doripenem, 1 g/ml (17 mm). e EUCAST breakpoints were as follows: for imipenem, 2 g/ml (23 mm) for …